|
1
|
McGuigan A, Kelly P, Turkington RC, Jones
C, Coleman HG and McCain RS: Pancreatic cancer: A review of
clinical diagnosis, epidemiology, treatment and outcomes. World J
Gastroenterol. 24:4846–4861. 2018.PubMed/NCBI
|
|
2
|
Urayama S: Pancreatic cancer early
detection: Expanding higher-risk group with clinical and
metabolomics parameters. World J Gastroenterol. 21:1707–1717.
2015.PubMed/NCBI
|
|
3
|
Deramaudt T and Rustgi AK: Mutant KRAS in
the initiation of pancreatic cancer. Biochim Biophys Acta.
1756:97–101. 2005.PubMed/NCBI
|
|
4
|
Maitra A, Kern SE and Hruban RH: Molecular
pathogenesis of pancreatic cancer. Best Pract Res Clin
Gastroenterol. 20:211–226. 2006.PubMed/NCBI
|
|
5
|
Cowan RW and Maitra A: Genetic progression
of pancreatic cancer. Cancer J. 20:80–84. 2014.PubMed/NCBI
|
|
6
|
Silverman BR and Shi JQ: Alterations of
epigenetic regulators in pancreatic cancer and their clinical
implications. Int J Mol Sci. 17(pii): E21382016.PubMed/NCBI
|
|
7
|
Baylin SB and Herman JG: DNA
hypermethylation in tumorigenesis: Epigenetics joins genetics.
Trends Genet. 16:168–174. 2000.PubMed/NCBI
|
|
8
|
Brait M, Ling S, Nagpal JK, Chang X, Park
HL, Lee J, Okamura J, Yamashita K, Sidransky D and Kim MS: Cysteine
dioxygenase 1 is a tumor suppressor gene silenced by promoter
methylation in multiple human cancers. Cancer Res.
7:e449512012.
|
|
9
|
Jeschke J, O'Hagan HM, Zhang W, Vatapalli
R, Calmon MF, Danilova L, Nelkenbrecher C, Van Neste L, Bijsmans
IT, Van Engeland M, et al: Frequent inactivation of cysteine
dioxygenase type 1 contributes to survival of breast cancer cells
and resistance to anthracyclines. Clin Cancer Res. 19:3201–3211.
2013.PubMed/NCBI
|
|
10
|
Kwon J, Park M, Kim JH, Lee HW, Kang MC
and Park JH: Epigenetic regulation of the novel tumor suppressor
cysteine dioxygenase 1 in esophageal squamous cell carcinoma.
Tumour Biol. 36:7449–7456. 2015.PubMed/NCBI
|
|
11
|
Deckers IA, Schouten LJ, Van Neste L, van
Vlodrop IJ, Soetekouw PM, Baldewijns MM, Jeschke J, Ahuja N, Herman
JG, van den Brandt PA and van Engeland M: Promoter methylation of
CDO1 identifies clear-cell renal cell cancer patients with poor
survival outcome. Clin Cancer Res. 21:3492–3500. 2015.PubMed/NCBI
|
|
12
|
Vedeld HM, Andresen K, Eilertsen IA,
Nesbakken A, Seruca R, Gladhaug IP, Thiis-Evensen E, Rognum TO,
Boberg KM and Lind GE: The novel colorectal cancer biomarkers CDO1,
ZSCAN18 and ZNF331 are frequently methylated across
gastrointestinal cancers. Int J Cancer. 136:844–853.
2015.PubMed/NCBI
|
|
13
|
Minatani N, Waraya M, Yamashita K, Kikuchi
M, Ushiku H, Kojo K, Ema A, Nishimiya H, Kosaka Y, Katoh H, et al:
Prognostic significance of promoter DNA Hypermethylation of
cysteine dioxygenase 1 (CDO1) Gene in primary breast cancer. PLoS
One. 11:e01448622016.PubMed/NCBI
|
|
14
|
Wrangle J, Machida EO, Danilova L, Hulbert
A, Franco N, Zhang W, Glöckner SC, Tessema M, Van Neste L, Easwaran
H, et al: Functional identification of cancer-specific methylation
of CDO1, HOXA9, and TAC1 for the diagnosis of lung cancer. Clin
Cancer Res. 20:1856–1864. 2014.PubMed/NCBI
|
|
15
|
Tham C, Chew M, Soong R, Lim J, Ang M,
Tang C, Zhao Y, Ong SY and Liu YQ: Postoperative serum methylation
levels of TAC1 and SEPT9 are independent predictors of recurrence
and survival of patients with colorectal cancer. Cancer.
120:3131–3141. 2014.PubMed/NCBI
|
|
16
|
Misawa K, Mochizuki D, Imai A, Endo S,
Mima M, Misawa Y, Kanazawa T, Carey TE and Mineta H: Prognostic
value of aberrant promoter hypermethylation of tumor-related genes
in early-stage head and neck cancer. Oncotarget. 7:26087–26098.
2016.PubMed/NCBI
|
|
17
|
Liu MY, Zhang H, Hu YJ, Chen YW and Zhao
XN: Identification of key genes associated with cervical cancer by
comprehensive analysis of transcriptome microarray and methylation
microarray. Oncol Lett. 12:473–478. 2016.PubMed/NCBI
|
|
18
|
Pelosof L, Yerram SR, Ahuja N, Delmas A,
Danilova L, Herman JG and Azad NS: CHFR silencing or microsatellite
instability is associated with increased antitumor activity of
docetaxel or gemcitabine in colorectal cancer. Int J Cance.
134:596–605. 2014.
|
|
19
|
Cleven AHG, Derks S, Draht MX, Smits KM,
Melotte V, Van Neste L, Tournier B, Jooste V, Chapusot C,
Weijenberg MP, et al: CHFR promoter methylation indicates poor
prognosis in stage II microsatellite stable colorectal cancer. Clin
Cancer Res. 20:3261–3271. 2014.PubMed/NCBI
|
|
20
|
Li Y, Yang Y, Lu Y, Herman JG, Brock MV,
Zhao P and Guo M: Predictive value of CHFR and MLH1 methylation in
human gastric cancer. Gastric Cancer. 18:280–287. 2015.PubMed/NCBI
|
|
21
|
Sepulveda JL, Gutierrez-Pajares JL, Luna
A, Yao Y, Tobias JW, Thomas S, Woo Y, Giorgi F, Komissarova EV,
Califano A, et al: High-definition CpG methylation of novel genes
in gastric carcinogenesis identified by next-generation sequencing.
Mod Pathol. 29:182–193. 2016.PubMed/NCBI
|
|
22
|
Ordóñez-Mena JM, Schöttker B, Mons U,
Jenab M, Freisling H, Bueno-de-Mesquita B, O'Doherty MG, Scott A,
Kee F, Stricker BH, et al: Quantification of the smoking-associated
cancer risk with rate advancement periods: Meta-analysis of
individual participant data from cohorts of the CHANCES consortium.
BMC Med. 14:622016.PubMed/NCBI
|
|
23
|
de Menezes RF, Bergmann A and Thuler LC:
Alcohol consumption and risk of cancer: A systematic literature
review. Asian Pac J Cancer Prev. 14:4965–4972. 2013.PubMed/NCBI
|
|
24
|
Rahimi E, Batra S, Thosani N, Singh H and
Guha S: Increased incidence of second primary pancreatic cancer in
patients with prior colorectal cancer: A population-based US study.
Dig Dis Sci. 61:1652–1660. 2016.PubMed/NCBI
|
|
25
|
Chung JW, Chung MJ, Bang S, Park SW, Song
SY, Chung JB and Park JY: Assessment of the risk of colorectal
cancer survivors developing a second primary pancreatic cancer. Gut
Liver. 11:728–732. 2017.PubMed/NCBI
|
|
26
|
Guo M, Jia Y, Yu Z, House MG, Esteller M,
Brock MV and Herman JG: Epigenetic changes associated with
neoplasms of the exocrine and endocrine pancreas. Discov Med.
17:67–73. 2014.PubMed/NCBI
|
|
27
|
Henriksen SD, Madsen PH, Larsen AC,
Johansen MB, Drewes AM, Pedersen IS, Krarup H and Thorlacius-Ussing
O: Cell-free DNA promoter hypermethylation in plasma as a
diagnostic marker for pancreatic adenocarcinoma. Clin Epigenetics.
8:1172016.PubMed/NCBI
|
|
28
|
Henriksen SD, Madsen PH, Larsen AC,
Johansen MB, Pedersen IS, Krarup H and Thorlacius-Ussing O:
Promoter hypermethylation in plasma-derived cell-free DNA as a
prognostic marker for pancreatic adenocarcinoma staging. Int J
Cancer. 141:2489–2497. 2017.PubMed/NCBI
|
|
29
|
Sun Z, Liu J, Jing H, Dong SX and Wu J:
The diagnostic and prognostic value of CHFR hypermethylation in
colorectal cancer, a meta-analysis and literature review.
Oncotarget. 8:89142–89148. 2017.PubMed/NCBI
|
|
30
|
Ding Y, Lian HF and Du Y:
Clinicopathological significance of CHFR promoter methylation in
gastric cancer: A meta-analysis. Oncotarget. 9:10083–10090.
2017.PubMed/NCBI
|
|
31
|
Bosman FT, Carneiro F, Hruban RH and
Theise ND: WHO classification of tumours of the digestive system.
World Health Organization. 2010.
|
|
32
|
Brierley JD, Gospodarowicz M and Wittekind
C: UICC International union against cancer. TNM classification of
malignant tumors 8th edn. Wiley-Blackwell. 2017.
|
|
33
|
Hulbert A, Jusue-Torres I, Stark A, Chen
C, Rodgers K, Lee B, Griffin C, Yang A, Huang P, Wrangle J, et al:
Early detection of lung cancer using DNA promoter hypermethylation
in plasma and sputum. Clin Cancer Res. 23:1998–2005.
2017.PubMed/NCBI
|
|
34
|
Silver N, Best S, Jiang J and Thein SL:
Selection of housekeeping genes for gene expression studies in
human reticulocytes using real-time PCR. BMC Mol Biol.
7:332006.PubMed/NCBI
|
|
35
|
Oien DB and Moskovitz J: Ablation of the
mammalian methionine sulfoxide reductase A affects the expression
level of cysteine deoxygenase. Biochem Biophys Res Commun.
352:556–559. 2007.PubMed/NCBI
|
|
36
|
Patak E, Pinto FM, Story ME, Pintado CO,
Fleming A, Page NM, Pennefather JN and Candenas ML: Functional and
molecular characterization of tachykinins and tachykinin receptors
in the mouse uterus. Biol Reprod. 72:1125–1133. 2005.PubMed/NCBI
|
|
37
|
Rameshwar P and Gascón P: Induction of
negative hematopoietic regulators by neurokinin-A in bone marrow
stroma. Blood. 88:98–106. 1996.PubMed/NCBI
|
|
38
|
Patai ÁV, Barták BK, Péterfia B, Micsik T,
Horváth R, Sumánszki C, Péter Z, Patai Á, Valcz G, Kalmár A, et al:
Comprehensive DNA methylation and mutation analyses reveal a
methylation signature in colorectal sessile serrated adenomas.
Pathol Oncol Res. 23:589–594. 2017.PubMed/NCBI
|
|
39
|
Kang D, Chen J, Wong J and Fang G: The
checkpoint protein Chfr is a ligase that ubiquitinates Plk1 and
inhibits Cdc2 at the G2 to M transition. J Cell Biol. 156:249–259.
2002.PubMed/NCBI
|
|
40
|
Shibata Y, Haruki N, Kuwabara Y, Ishiguro
H, Shinoda N, Sato A, Kimura M, Koyama H, Toyama T, Nishiwaki T, et
al: Chfr expression is downregulated by CpG island hypermethylation
in esophageal cancer. Carcinogenesis. 23:1695–1699. 2002.PubMed/NCBI
|
|
41
|
Yun T, Liu Y, Gao D, Linghu E, Brock MV,
Yin D, Zhan Q, Herman JG and Guo M: Methylation of CHFR sensitizes
esophageal squamous cell cancer to docetaxel and paclitaxel. Genes
Cancer. 6:38–48. 2015.PubMed/NCBI
|
|
42
|
Von Hoff DD, Ervin T, Arena FP, Chiorean
EG, Infante J, Moore M, Seay T, Tjulandin SA, Ma WW, Saleh MN, et
al: Increased survival in pancreatic cancer with nab-paclitaxel
plus gemcitabine. N Engl J Med. 369:1691–1703. 2013.PubMed/NCBI
|
